大跌12%，艾伯维精神分裂症药物研究失败

生物药大时代2024-11-12

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。11月12日，艾伯维宣布其用于治疗精神分裂症的M4激动剂Emraclidine在两项名为EMPOWER-1和EMPOWER-2的临床二期试验中，未达到其主要终点。这意味着与安慰剂相比，Emraclidine在改善PANSS（Positive and ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2482715620?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-11-12 10:25","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2482715620","market":"us","top_or_hot":-1,"title":"大跌12%，艾伯维精神分裂症药物研究失败","media":"生物药大时代","content":"<div>\n<p>声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。11月12日，艾伯维宣布其用于治疗精神分裂症的M4激动剂Emraclidine在两项名为EMPOWER-1和EMPOWER-2的临床二期试验中，未达到其主要终点。这意味着与安慰剂相比，Emraclidine在改善PANSS（Positive and ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112102656a22e351d&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>大跌12%，艾伯维精神分裂症药物研究失败</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n大跌12%，艾伯维精神分裂症药物研究失败\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-12 10:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112102656a22e351d&s=b><strong>生物药大时代</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。11月12日，艾伯维宣布其用于治疗精神分裂症的M4激动剂Emraclidine在两项名为EMPOWER-1和EMPOWER-2的临床二期试验中，未达到其主要终点。这意味着与安慰剂相比，Emraclidine在改善PANSS（Positive and ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112102656a22e351d&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0417517546.SGD","symbol_name":"Allianz US Equity Cl AT Acc SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112102656a22e351d&s=b","article_id":"2482715620","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112102656a22e351d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2482715620","pubTimestamp":1731378301,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月12日，艾伯维宣布其用于治疗精神分裂症的M4激动剂Emraclidine在两项名为EMPOWER-1和EMPOWER-2的临床二期试验中，未达到其主要终点。2023年12月，艾伯维以87亿美元收购了Cerevel Therapeutics及其后期资产Emraclidine。它通过选择性地调节M4受体来减少多巴胺信号，而不需要阻断D2受体，这可能减少现有抗精神病药物的副作用。Emraclidine的临床试验失败对AbbVie来说是一个重大打击，受此消息的影响，艾伯维股价大跌超12%，市值蒸发约 400 亿美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","PAM":"Pampa Energia S.A.","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","LU0545039389.USD":"BGF GLOBAL EQUITY INCOME \"A2\" ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","BK4559":"巴菲特持仓","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4566":"资本集团","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","BK4581":"高盛持仓","LU0965508806.USD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0158827948.USD":"ALLIANZ GLOBAL SUSTAINABILITY \"A\" (USD) INC","BK4563":"昨日强势股","LU0949170772.SGD":"Blackrock Global Equity Income A6 SGD-H","LU0861579265.USD":"联博低波幅策略股票基金A","LU0122379950.USD":"贝莱德世界健康科学A2","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU1003077747.HKD":"BGF GLOBAL EQUITY INCOME \"A6\" (HKDHDG) INC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00B3PB1722.GBP":"GUINNESS GLOBAL EQUITY INCOME \"C\" (GBP) INC","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU0738911758.USD":"Blackrock Global Equity Income A6 USD","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","ABBV":"艾伯维公司","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0553294199.USD":"BGF GLOBAL EQUITY INCOME \"A5G\" (USD) INC"},"translate_title":"Plunging 12%, AbbVie's schizophrenia drug study fails","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PAM":1,"ABBV":0.9},"content_text":"声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。11月12日，艾伯维宣布其用于治疗精神分裂症的M4激动剂Emraclidine在两项名为EMPOWER-1和EMPOWER-2的临床二期试验中，未达到其主要终点。这意味着与安慰剂相比，Emraclidine在改善PANSS（Positive and Negative Syndrome Scale）总分方面没有统计学上的显著差异。2023年12月，艾伯维以87亿美元收购了Cerevel Therapeutics及其后期资产Emraclidine。Emraclidine是一种毒蕈碱M4受体的正变构调节剂（PAM），被认为是一种潜在的下一代抗精神病药物。它通过选择性地调节M4受体来减少多巴胺信号，而不需要阻断D2受体，这可能减少现有抗精神病药物的副作用。Emraclidine的临床试验失败对AbbVie来说是一个重大打击，受此消息的影响，艾伯维股价大跌超12%，市值蒸发约 400 亿美元。与此同时，BMS的股价因Emraclidine的失败而上涨约12%，这是自2006年3月以来的最高单日涨幅。该公司的 Cobenfy （也称KarXT）产品是一款可以与之竞争的药物。BMS通过以 140 亿美元的价格收购 Karuna Therapeutics 获得了这种药物，该交易于 3 月完成。KarXT是同类药物中第一种具有真正新颖和独特双重机制的潜在药物，由呫诺美林（xanomeline）和trospium组成，其中呫诺美林是M1和M4两种亚型的激动剂，而trospium是M受体的拮抗剂，旨在激活大脑中的毒蕈碱型乙酰胆碱受体的同时，减少对外周毒蕈碱型乙酰胆碱受体的作用。参考资料：www.endpts.com各公司官网","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2482715620"}